# Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

> **NCT03948178** · PHASE3 · TERMINATED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 227 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Levosimendan

## Key facts

- **NCT ID:** NCT03948178
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-26
- **Primary completion:** 2020-11-18
- **Final completion:** 2020-11-18
- **Target enrollment:** 227 (ACTUAL)
- **Why stopped:** This was an open label extension for patients completing the REFALS study (3119002; NCT03505021). Study 3119002 showed lack of efficacy of ODM109 so the sponsor decided to terminate this study
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03948178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03948178, "Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03948178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*